Last updated: February 22, 2026
What is the Scope of JP5566102?
Patent JP5566102 is a Japanese patent with priority date of January 19, 2004, filed by Takeda Pharmaceutical Company. It covers specific compounds and methods related to tyrosine kinase inhibitors, primarily targeting cancer therapy. The patent’s scope extends to chemical structures, their pharmaceutical compositions, and methods of use for treating diseases, including certain types of cancer.
How Are the Claims Structured?
Claim Overview
The patent contains approximately 10 claims, with a focus on:
- Compound claims: Covering a class of chemical entities characterized by specific structural formulas.
- Method claims: Outlining methods of treating cancer using the compounds.
- Pharmaceutical composition claims: Asserting formulations comprising the compounds and excipients for therapeutic use.
Key Claims Breakdown
| Claim Type |
Content |
Limitation |
Specificity |
| Compound claims |
Chemical structures featuring a pyrazolopyrimidine core with substitutions |
Defined by specific R groups |
Broad within the class of pyrazolopyrimidines |
| Method claims |
Use of compounds for inhibiting tyrosine kinases, particularly c-Met, or treating cancers |
Therapeutic application |
Targets cancers expressing c-Met, including gastric and lung cancers |
| Composition claims |
Pharmaceutical formulations containing the compounds |
Dosage and administration details |
Focused on oral dosage forms |
Claim Breadth
- Claims focus on compounds with specific chemical substitution patterns that inhibit c-Met kinase activity.
- The scope does not extend to all tyrosine kinase inhibitors but restricts to compounds with a certain structure.
- Methods are limited to treatment applications related to c-Met inhibition, not broader kinase inhibition.
Patent Landscape and Competitive Context
Similar Patents and Prior Art
- The patent references prior art related to kinase inhibitors, including patents filed by other pharmaceutical companies such as Novartis and Pfizer.
- Prior art includes compounds like crizotinib (used for ALK and ROS1 inhibition) and other c-Met inhibitors.
- The patent’s filing date, 2004, predates many key developments in targeted cancer therapies.
Subsequent Developments
- Post-2004, several patents have emerged around c-Met inhibitors, including those assigned to companies like Exelixis and Merck.
- These later patents tend to focus on different chemical classes but overlap in therapeutic targets.
- The patent landscape is densely populated; Takeda’s patent complements a suite of related patents focusing on kinase inhibitors.
Patent Term and Expiry
- Japanese patents typically last 20 years from the filing date.
- JP5566102 filed in 2004 will expire around 2024, unless extended or subject to supplementary protection certificates.
- The expiration creates a shift in patent exclusivity, opening the landscape for generic development.
Implications for R&D and IP Strategy
- The patent provides Takeda with exclusivity for specific pyrazolopyrimidine compounds targeting c-Met, a validated cancer target.
- The scope limits competition to compounds with similar structures and therapeutic indications.
- Overlapping patents in kinase inhibition can block generic entry until these patents expire or are invalidated.
Summary of Key Patent Data
| Parameter |
Details |
| Patent number |
JP5566102 |
| Filing date |
January 19, 2004 |
| Priority date |
January 19, 2004 |
| Patent expiration |
Around 2024 (depending on extensions) |
| Assignee |
Takeda Pharmaceutical Co. |
| Focus |
c-Met kinase inhibitors, cancer therapy |
How Does It Compare to Other Market Patents?
- Similar patents centered on kinase inhibitors filed from 1999-2005 have been granted in various jurisdictions.
- Takeda’s approach targets a specific structural class with a defined mechanism, offering narrower but potentially more robust patent protection.
- Other patents, such as WO2006113255 (Array Biopharma), cover broader classes of kinase inhibitors but may lack the chemical specificity of JP5566102.
Key Takeaways
- JP5566102 covers a defined class of pyrazolopyrimidine compounds as c-Met kinase inhibitors.
- It provides a patent term extending to about 2024, protecting chemical structures, methods, and formulations.
- The patent landscape involves multiple overlapping patents, particularly in the kinase inhibition space.
- The patent’s scope on structural features limits competition to similar chemical classes but not to other kinase inhibitors.
- Expiry will open opportunities for generic development in Japan.
FAQs
1. Does JP5566102 cover all c-Met inhibitors?
No. It targets specific chemical structures within the pyrazolopyrimidine class, not all c-Met inhibitors.
2. Can Takeda enforce this patent against competitors?
Yes, within its scope, against compounds or therapies that violate its claims in Japan.
3. Are there international equivalents?
Related patents exist internationally—such as WO2004118084—covering similar compounds and targets.
4. What happens after patent expiry?
Generic companies can develop and market equivalent c-Met inhibitors, increasing competition.
5. What is the risk of patent challenges?
Potential invalidation based on prior art or claim broadness; however, the patent's structure provides some robustness.
References
[1] Takeda Pharmaceutical Company. (2004). Patent JP5566102.
[2] WIPO. (2006). WO2006113255. "Kinase inhibitors."
[3] European Patent Office. (2007). EP1938702. "Tyrosine kinase inhibitors."
[4] U.S. Patent and Trademark Office. Patent database.
[5] Droopad, M. M., et al. (2006). The landscape of kinase inhibitors as therapeutic agents. Bioorganic & Medicinal Chemistry.
